Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of medical examination specialist ExamWorks
So what: ExamWorks' second-quarter top and bottom lines ($72 million and $106.7 million, respectively) were pretty much in line with analyst estimates, but it's obvious that some big shareholders wanted a lot more. In fact, the shares are flirting with the lowest point they've seen since the company's late-October IPO.
Now what: I'd cautiously look into this plunge as a possible buying opportunity. Management's full-year revenue outlook of between $405 million and $415 million was also in line with Wall Street estimates, making today's nasty sell-off all the more baffling -- and potentially profitable. If ExamWorks is truly, in Chairman Richard Perlman's words, "ideally positioned to sustain this high-growth rate," today's buyers should be nicely positioned as well.
Interested in more info on ExamWorks? Add it to your watchlist.